BeOne Medicines
Angie Chen, PhD, PMP, serves as Senior Director and Head of Global Strategic Feasibility at BeiGene, where responsibilities include building global strategic feasibility capabilities and optimizing clinical trial delivery. Previously, Angie held various leadership roles at AstraZeneca, including Associate Director of Study Management and Global Study Leader, focusing on the execution and management of clinical studies. Additional experience includes positions as Global Study Associate Manager at AstraZeneca, Research Associate and Postdoctoral Fellow at the University Health Network and the University of Toronto, Clinical Trial Leader at Novartis, and Medical Writer at Novo Nordisk A/S. Angie holds a PhD in Medical Sciences-Psychiatry from The Chinese University of Hong Kong, a Master's Degree in Biochemistry from Indiana University Bloomington, and a Bachelor's Degree in Life Sciences from Peking University.
This person is not in any teams
This person is not in any offices
BeOne Medicines
36 followers
BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them.